Angiotensin Converting Enzyme 2 News and Research

RSS

A map of SARS-CoV-2 escape mutations enables the development of therapeutic antibody cocktails

A recent tour-de-force study by the US researchers describes a comprehensive approach to completely map mutations to the SARS-CoV-2 receptor-binding domain (RBD) that escape antibody binding – enabling, in turn, rational design of antibody therapeutics and appraisal of the antigenic consequences of viral evolution. The results are currently available in a bioRxiv preprint paper.

13 Sep 2020

Study sheds light on the disproportionate impact of COVID-19 on Blacks

In a study published in JAMA today, Mount Sinai researchers report findings that shed some light on the disproportionate impact of COVID-19 on Blacks, who have experienced rates of infection and death that are much greater, in some areas twice and three times more, than their proportion of the population.

11 Sep 2020

Researchers explore IgA response to SARS-CoV-2

A new study published on the preprint server bioRxiv* and conducted by researchers from The Rockefeller University in New York examined the role of IgA antibodies in preventing SARS-CoV-2 infection. In this study, the team analyzed the IgA response to SARS-CoV-2 infection in 149 individuals.

10 Sep 2020

Researchers say Influenza may increase risk of COVID-19

A recent study by researchers suggests that the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is influenced by influenza virus infection during the initial period of coronavirus disease 2019 (COVID-19) pandemic in Europe. The study is currently available on the medRxiv preprint server.

10 Sep 2020

Scientists explain how SARS-CoV-2 attacks the brain

Now, a team of scientists at Yale University revealed the changes that happen in the brain caused by SARS-CoV-2, the virus that has caused over 27.86 million people and claimed over 903,000 lives.

10 Sep 2020

Brain inflammation seen in fatal COVID-19 cases

Now, a new study by researchers at the Barts Health NHS Trust and the University of Cambridge in the United Kingdom shows that some patients develop neurological complications tied to COVID-19.

9 Sep 2020

Susceptibility to SARS-CoV-2 infection varies across bat species

A recent study by researchers at Wuhan University, China, reveals that many bat species are not potential carriers of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) because of genetic mutations in angiotensin-converting enzyme 2 (ACE2) that prevent the entry of viruses inside bat cells. The study is currently available on the bioRxiv* preprint server.

9 Sep 2020

Pfizer, BioNTech COVID-19 vaccine candidate shows promise in preclinical study

Researchers in the United States and Germany have conducted a study demonstrating the preclinical efficacy of a new candidate vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

9 Sep 2020

Host gene editing main driving force of SARS-CoV-2 mutations

A new study published on the aRxiv preprint server in September 2020 shows that the host immune response, mediated by two RNA editors, causes the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to adapt and change strain characteristics.

9 Sep 2020

Limited gut inflammation in COVID-19

A new study by researchers at the Icahn School of Medicine at Mount Sinai and published on the preprint server medRxiv in September 2020 shows that gut infection with this virus produces primarily mucosal immunity but also a limited inflammatory response.

8 Sep 2020

Scientists describe various dynamic structures of the SARS-CoV-2 spike protein

Early in the pandemic, scientists uncovered the role of the ACE2 receptor in SARS-CoV-2, the virus that causes the coronavirus disease (COVID-19). The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and the angiotensin-converting enzyme 2 (ACE2) receptors act as a lock and key for cell infection.

7 Sep 2020

PI3K/mTOR and topoisomerase inhibitors suggested as candidates to reduce expression of ACE2

A recent study published in the preprint server medRxiv in September 2020 shows that the already approved drug families called P13K/mTOR and topoisomerase inhibitors may be useful in reducing individual susceptibility to the virus.

7 Sep 2020

Study shows SARS-CoV-2 cell receptor is a novel target of the gamma-secretase enzyme complex

Based on structural similarities with other targets of the gamma-secretase system, researchers from Columbia University Irving Medical Center in the United States show that the SARS-CoV-2 receptor for cell entry may be affected by its proteolytic activity. Their results are currently freely available in a bioRxiv preprint paper.

6 Sep 2020

Spike-based priming leads to high neutralizing activity in animal models

A new report by researchers at the University of Melbourne and published on the preprint server bioRxiv in September 2020 reports on the use of a two-protein two-dose vaccine regimen and its immunogenicity in two animal models.

4 Sep 2020

D614G spike mutation increases infectivity of SARS-CoV-2 and neutralization susceptibility

As the COVID-19 pandemic progresses, it is crucial to track the viral changes in order to link the clinical and epidemiological features of the disease with these mutations. A new study published on the preprint server bioRxiv* in September 2020 reports on a common severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutation, D614G, and its effects on the virus.

4 Sep 2020

ACE2/TMPRSS2 not expressed in pancreatic islet endocrine cells

A new study by researchers at the Vanderbilt University Medical Center and the University of Pennsylvania Perelman School of Medicine and published on the preprint server bioRxiv* in August 2020 reports that both key enzymes that are required for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entry into the human host cell are lacking in the beta cells of the pancreatic islet. This rules out the direct injury hypothesis for impaired glucose control in patients with COVID-19 disease.

1 Sep 2020

Negligible ACE2 expression in human beta-cells

Now, a new study published on the preprint server bioRxiv reports that even though the fatality rate is significantly higher in diabetics, there is no evidence that this is due to direct viral infection of pancreatic beta cells, which produce the key hormone in glucose homeostasis, namely insulin.

1 Sep 2020

Promising new candidate 'virus-like particle' vaccine for COVID-19

Researchers in the UK and Taiwan have demonstrated the potential of a new candidate vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the virus responsible for the current coronavirus disease 2019 (COVID-19) pandemic.

1 Sep 2020

Common heart drugs are safe for patients hospitalized with COVID-19

Heart patients hospitalized with COVID-19 can safely continue taking angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), according to the BRACE CORONA trial presented in a Hot Line session today at ESC Congress 2020.

1 Sep 2020

Spike ferritin nanoparticles show potential as SARS-CoV-2 vaccine

Now, a new study published on the preprint server bioRxiv* in August 2020 reports the induction of neutralizing antibodies in mice by a single dose of a ferritin nanoparticle-based vaccine containing the spike protein.

1 Sep 2020